Cara Therapeutics, Inc. (NASDAQ:CARA) Stake Maintained by Alliancebernstein L.P.
Alliancebernstein L.P. continued to hold its position in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,300 shares of the biopharmaceutical company’s stock at the end of the first quarter. Alliancebernstein L.P. owned about 0.07% of Cara Therapeutics worth $373,000 as of its most recent filing with the SEC.
Other institutional investors also recently made changes to their positions in the company. American International Group Inc. boosted its position in shares of Cara Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,937 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 857 shares in the last quarter. Stifel Financial Corp acquired a new stake in shares of Cara Therapeutics during the first quarter worth $2,123,000. Quantbot Technologies LP acquired a new stake in shares of Cara Therapeutics during the first quarter worth $124,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Cara Therapeutics during the first quarter worth $476,000. Finally, Private Advisor Group LLC boosted its stake in shares of Cara Therapeutics by 120.5% in the first quarter. Private Advisor Group LLC now owns 23,737 shares of the biopharmaceutical company’s stock worth $417,000 after buying an additional 12,970 shares during the period. Institutional investors own 52.75% of the company’s stock.
Shares of Cara Therapeutics, Inc. (CARA) traded up 0.79% on Friday, hitting $13.96. 885,383 shares of the stock traded hands. The stock’s 50 day moving average price is $16.04 and its 200 day moving average price is $16.39. Cara Therapeutics, Inc. has a 52-week low of $5.27 and a 52-week high of $28.50. The stock’s market cap is $454.83 million.
Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.32. During the same quarter in the previous year, the company posted ($0.48) earnings per share. The company’s revenue was down 100.0% compared to the same quarter last year. On average, equities analysts expect that Cara Therapeutics, Inc. will post ($1.78) EPS for the current fiscal year.
A number of equities research analysts have weighed in on the stock. Vetr upgraded shares of Cara Therapeutics from a “hold” rating to a “buy” rating and set a $27.58 price objective on the stock in a report on Wednesday, June 28th. Janney Montgomery Scott restated a “buy” rating and issued a $22.00 price objective on shares of Cara Therapeutics in a report on Wednesday, June 28th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price objective (down previously from $24.00) on shares of Cara Therapeutics in a report on Friday, June 30th. Laidlaw cut their price objective on shares of Cara Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, June 30th. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Cara Therapeutics in a report on Wednesday, June 21st. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Cara Therapeutics presently has an average rating of “Buy” and an average price target of $25.18.
In other news, VP Frederique Ph.D. Menzaghi sold 3,000 shares of Cara Therapeutics stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $15.00, for a total value of $45,000.00. Following the transaction, the vice president now owns 120,000 shares of the company’s stock, valued at approximately $1,800,000. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Derek T. Chalmers sold 25,000 shares of Cara Therapeutics stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $15.05, for a total transaction of $376,250.00. Following the completion of the transaction, the chief executive officer now directly owns 1,107,292 shares in the company, valued at approximately $16,664,744.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 278,000 shares of company stock worth $6,888,750. Insiders own 7.70% of the company’s stock.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Want to see what other hedge funds are holding CARA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cara Therapeutics, Inc. (NASDAQ:CARA).
Receive News & Stock Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related stocks with our FREE daily email newsletter.